The “Canadian Transfusion Adverse Event Reporting Form” (CTAERF) can be used for reporting to the Ontario Transfusion Transmitted Injuries Surveillance System (TTISS-ON), Canadian Blood Services (CBS), Canada Vigilance Program (Health Canada) and Manufacturers of Plasma Derivatives. To download the CTAERF go to: http://www.transfusionmedicine.ca/sites/transfusionmedicine/files/ctaer_form-eng.pdf

Note: Remove patient name and OHIP number before faxing or emailing the CTAERF.

1. Reporting to Ontario Transfusion Transmitted Injuries Surveillance System (TTISS-ON)
   All reactions (excluding minor allergic, febrile non-hemolytic and delayed serological) are reportable to TTISS-ON, including those that are not required to be reported to the Canada Vigilance Program, CBS or the Manufacturer of Plasma Derivative (e.g. Acute Hemolytic reaction due to a mislabelled specimen). TTISS-ON reports aggregate de-identified data to the Public Health Agency of Canada as part of the National TTISS program.

   • Enter information collected using the CTAERF into the REDCap TTISS-ON database at https://ttiss.mcmaster.ca or FAX the CTAERF to 905-524-2983 (Attention: TTISS)

   • To obtain a password to enter information in the TTISS-ON database, fill out the contact information form by clicking the link: https://ttiss.mcmaster.ca/surveys/?s=R7EEM83X7A

   • For more information about TTISS-ON contact:
     Joanne Duncan, TTISS Ontario Coordinator, McMaster University, Hamilton
     Tel: 905-525-9140 ext. 22934 Email: duncanj@mcmaster.ca

2. Reporting to the Canada Vigilance Program (as per Health Canada Blood Regulations)
   Refer to Page 2 and FAX or Mail the CTAERF to:
   • Canada Vigilance Program
   • Marketed Health Products and Effectiveness Information Bureau
   • Marketed Health Products Directorate/Health Products and Food Branch
   • Health Canada, Postal Locator: 0701E
   • Ottawa, Ontario K1A 0K9
   • Fax (613) 957-0335 Telephone (613) 957-0337
   • E-mail: CanadaVigilance@hc-sc.gc.ca (Do not send reports via email, for inquiries only)

   For reporting to Health Canada under the Medical Device Regulations:

3. Reporting to Canadian Blood Services (CBS)
   Refer to Page 2 and FAX or mail the CTAERF to:
   • Your local Canadian Blood Services Distribution Department

   Note that if patient blood samples are being sent to CBS for testing, the patient’s name is required

4. Reporting to Manufacturer of Plasma Derivative
   Refer to Page 3 and FAX or Email the CTAERF to the appropriate Manufacturer of the implicated derivative. For contact information go to: https://www.blood.ca/en/hospitals/plasma-products and download the Manufacturer Contact List.
**Investigate and identify type of transfusion reaction**

**Referring to in this document as Adverse Transfusion Event (ATE) and in the Blood Regulations as Adverse Recipient Reaction (ARR)

1. Is the ATE one of the following?
   - Minor Allergic
   - Febrile Non-Hemolytic
   - Delayed Serological

2. Yes
   - No Further Reporting Required

3. No
   - Is the ATE attributable to an activity at the hospital that affected the safety/efficacy of the component?
     - Examples:
       - ATEs due to mislabeling of the component by the TML (e.g. unirradiated blood labelled as irradiated)
       - Bacterial contamination due to pooling of component at the hospital or storing of blood in a malfunctioning fridge
       - REPORT TO BOTH the Canadian Blood Services and the Canada Vigilance Program if it is not clear whether an ATE is due to a hospital activity that affected the component or the component itself (e.g. contamination)

4. Yes
   - Report ATE to Canada Vigilance Program
   - (Health Canada Blood Regulations)
   - FAX or mail CTAERF within 24 hours of a fatality, otherwise within 15 days
   - (see Instructions p.1)
   - Final report is required once investigation is complete

5. No
   - Is the ATE one of the following?
     - Transfusion-Related Acute Lung Injury (TRALI or Possible TRALI)
     - Severe allergic reaction/anaphylaxis
     - Bacterial contamination
     - Post transfusion infection (e.g. HIV, Hepatitis, Chagas, Malaria, West Nile)
     - Adverse events due to suspected CBS mislabelling
     - Unexplained new acute severe neutropenia or thrombocytopenia (transfusion-related alloimmune neutropenia or thrombocytopenia)
     - Other unusual reaction where the hospital is concerned the blood component is the cause

6. Yes
   - Report ATE to Ontario Transfusion Transmitted Injuries Surveillance System (TTISS-ON)
   - Enter data directly into the TTISS-ON web database or send CTAERF by FAX within 3 months
   - (see Instructions p.1)

7. No
   - Report ATE to Canadian Blood Services (CBS)
   - FAX the CTAERF to local Medical Office
   - (see Instructions p.1)
   - Report the ATE immediately if fatality or if suspected to be attributable to quality of component (e.g. bacterial or viral contamination).
   - Otherwise as soon as possible.

8. Note: CBS reports as required to the Canada Vigilance Program

Developed by the TTISS-ON Education Committee - Version 2: 2017
Investigate and identify type of transfusion reaction**
**Referred to in this document as Adverse Transfusion Event (ATE)

Could the ATE have been caused by an activity at the hospital that affected the safety/efficacy of the product or is the ATE due to a complication of transfusion practice or an error?

Examples: improper storage, contamination during pooling, Transfusion Associated Circulatory Overload (TACO)

REPORT TO BOTH the Manufacturer of the Plasma Derivative and TTISS-ON if it is not clear whether suspected bacterial contamination is due to an activity at the hospital

Is the ATE a minor reaction common to the plasma derivative?
(e.g. Minor Allergic)

COMPLETE the Canadian Transfusion Adverse Event Reporting Form (CTAERF) excluding patient name and OHIP No.

Is the ATE serious as defined by the Food and Drug Regulations?

Examples:
- Serious acute/delayed hemolytic reactions
- Aseptic meningitis
- Transfusion-Related Acute Lung Injury (TRALI or Possible TRALI)
- Severe allergic reaction/anaphylaxis
- Bacterial contamination
- Post transfusion infection (e.g. Hepatitis)
- Unexplained new acute severe neutropenia or thrombocytopenia (transfusion-related alloimmune neutropenia or thrombocytopenia)
- Other unusual reaction where the hospital is concerned the plasma derivative is the cause

Report ATE to the Manufacturer of Plasma Derivative

Fax or email the CTAERF to the appropriate manufacturer (see Instructions p.1)

Report the ATE immediately if fatality or if suspected to be attributable to product quality (e.g. bacterial or viral contamination). Otherwise as soon as possible.

Note: The manufacturer is required to report to the Canada Vigilance Program

Report ATE to Ontario Transfusion Transmitted Injuries Surveillance System (TTISS-ON)

Enter data directly into the TTISS-ON web database or send CTAERF by Fax to Ontario TTISS within 3 months (see Instructions p.1)
Acknowledgement

Created by the TTISS-ON Education Committee

Chair:

Ana Lima, Transfusion Safety Nurse, Sunnybrook Health Sciences Centre, Toronto

Members:

Donna Berta, Transfusion Safety Officer, London Hospitals
Christine M Cserti-Gazdewich, Transfusion Medicine Specialist & Consultant Hematologist, UHN
Nancy Cober, Medical Laboratory Technologist, Ottawa Area Hospitals
Leonar De Biasio, Clinical Project Coordinator, ORBCoN, Toronto
Joanne Duncan, TTISS-ON Coordinator, McMaster University, Hamilton
Alioska Escorcia, Transfusion Safety Officer, University Health Network
Laura Harrison, Transfusion Safety Officer, Trillium Health Partners, Mississauga
Nancy Heddle, Director of TTISS-ON, McMaster University, Hamilton
Kathleen McShane, Transfusion Safety Officer, Hospital for Sick Children
Kelly Syer, Transfusion Safety Officer, Lakeridge Health, Oshawa

The TTISS-ON Education Committee recognizes the valuable contribution made by representatives at the Canadian Blood Services Ontario, the Canada Vigilance and Marketed Products Division of Health Canada and several plasma derivative manufacturers. Thank you for the input, guidance and encouragement you provided throughout development.

Thank you to our TTISS-ON funding agencies; Ontario Ministry of Health and Long-Term Care and the Public Health Agency of Canada.